Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease

Biol Blood Marrow Transplant. 2018 Jan;24(1):19-26. doi: 10.1016/j.bbmt.2017.10.006. Epub 2017 Oct 12.

Authors

Kelli P A MacDonald¹, Brian C Betts², Daniel Couriel³

Affiliations

¹ Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: Kelli.MacDonald@qimrberghofer.edu.au.
² Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffit Cancer Center, Tampa, Florida.
³ Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah.

PMID: 29032060
DOI: 10.1016/j.bbmt.2017.10.006

No abstract available

Keywords: Allogeneic hematopoietic cell transplantation; Chronic GVHD; Graft-versus-host disease; Interleukin-17A; JAK inhibitor.

Publication types

Review

MeSH terms

Chronic Disease
Graft vs Host Disease / prevention & control*
Hematopoietic Stem Cell Transplantation / adverse effects
Humans
Interleukin-17 / immunology
Janus Kinase Inhibitors / immunology
Therapeutics / trends*
Transplantation, Homologous / adverse effects

Substances

Interleukin-17
Janus Kinase Inhibitors

Grants and funding

R01 HL133823/HL/NHLBI NIH HHS/United States